FDA Greenlights Tovorafenib for Pediatric Low Grade Glioma

433 Views

Emedinexus 19 June 2025

April 23, 2024 — The FDA has granted accelerated approval to tovorafenib for children six months and older with relapsed or refractory low-grade glioma characterized by BRAF fusion, rearrangement, or V600 mutation. This marks the first systemic therapy approved for pediatric low-grade gliomas driven by BRAF rearrangements or fusions

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.